Trodelvy (sacituzumab govitecan) is an antibody pharmaceutical. Sacituzumab govitecan was first approved as Trodelvy on 2020-04-22. It is used to treat triple negative breast neoplasms in the USA. The pharmaceutical is active against tumor-associated calcium signal transducer 2.
|Common Name||Sacituzumab govitecan|
|Indication||triple negative breast neoplasms|
|Drug Class||Monoclonal antibodies: humanized, tumors as target; antineoplastics (camptothecine derivatives)|